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Abstract
Objective: The effect of vitamin D at the transcriptome level is poorly understood, 
and furthermore, it is unclear if it differs between obese and normal-weight subjects. 
The objective of the study was to explore the transcriptome effects of vitamin D 
supplementation.
Design and methods: We analysed peripheral blood gene expression using GlobinLock 
oligonucleotides followed by RNA sequencing in individuals participating in a 12-week 
randomised double-blinded placebo-controlled vitamin D intervention study. The 
study involved 18 obese and 18 normal-weight subjects (of which 20 males) with mean 
(±s.d.) age 20.4 (±2.5) years and BMIs 36 (±10) and 23 (±4) kg/m2, respectively. The 
supplemental daily vitamin D dose was 50 µg (2000 IU). Data were available at baseline, 
6- and 12-week time points and comparisons were performed between the vitamin D 
and placebo groups separately in obese and normal-weight subjects.
Results: Significant transcriptomic changes were observed at 6 weeks, and only in 
the obese subjects: 1724 genes were significantly upregulated and 186 genes were 
downregulated in the vitamin D group compared with placebo. Further analyses showed 
several enriched gene categories connected to mitochondrial function and metabolism, 
and the most significantly enriched pathway was related to oxidative phosphorylation 
(adjusted P value 3.08 × 10−14). Taken together, our data suggest an effect of vitamin D 
supplementation on mitochondrial function in obese subjects.
Conclusions: Vitamin D supplementation affects gene expression in obese, but not 
in normal-weight subjects. The altered genes are enriched in pathways related to 
mitochondrial function. The present study increases the understanding of the effects of 
vitamin D at the transcriptome level.
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Introduction
Obesity and vitamin D deficiency represent frequent 
nutrition concerns worldwide and recent evidence links 
these together (1, 2, 3). Moreover, obesity and excess 
adipose tissue gain are suggested as a cause of vitamin D 
deficiency (3), defined as circulating 25-hydroxy vitamin D 
(25-OHD) concentration below 50 nmol/L (4). The 
underlying mechanism may involve a dilution effect of 
adipose tissue on circulating hormone concentration, 
and higher consumption of vitamin D by inflammatory 
processes in adipose tissue (5).
It is crucial to understand the metabolism and 
targeted effects of vitamin D and especially how these 
are affected in obesity. To date, we know that vitamin D 
supplementation increases circulating 25-OHD in obese 
individuals, although the effect is less pronounced than 
in normal-weight individuals. In contrast, the effect on 
biologically active, free 25-OHD is similar in the two 
groups (6). On the other hand, weight loss also has a 
beneficial effect on vitamin D status (7, 8, 9). However, 
studies comparing vitamin D supplementation and its 
effects on obese and normal-weight subjects are scarce, 
and well-planned studies are needed to reveal the effect 
on predefined outcomes. Defining the sufficiency of 
vitamin D should not be done solely based on the 
concentration of 25-OHD, but should be supported by 
additional information on the downstream effects of 
vitamin D. These mechanisms are likely to involve the 
genomic actions of vitamin D binding to vitamin D 
receptor (VDR), which is found in over 40 tissues (10) and 
modulates the expression of a large number of genes (11). 
Previous studies have mainly focused on the actions of 
vitamin D in specific cell lines as reviewed by Bouillon & 
colleagues (11), while the global transcriptomic effects of 
vitamin D are poorly understood.
Vitamin D deficiency is linked to a number of 
adverse health consequences (5, 12). For some of these, 
including cardiovascular disease, type 2 diabetes mellitus 
and metabolic syndrome, obesity is also a recognised 
contributor. It is essential to understand these risk 
factors and related molecular responses more in depth, 
and whether they are independent or interdependent. 
Recent applications of functional genomic approaches 
allow the systematic assessment of molecular responses 
in randomised trials, which unveil mechanisms of action 
in humans. This information will contribute to deeper 
understanding of the aetiology of the conditions, increase 
the efficacy of clinical trials and be valuable in the future 
prevention of chronic diseases.
We expanded a previously described 12-week 
randomised double-blinded placebo-controlled vitamin D 
intervention study involving both obese and normal-
weight subjects (6). The objective of the present study was 
to examine the effect of vitamin D supplementation on 
gene expression levels in white blood cells separately in 
obese and normal-weight subjects, at three time points. 
Our findings yield insight into transcriptome changes 
connected to mitochondrial function unique to obese 
subjects at the 6-week time point.
Materials and methods
Materials
We analysed the material collected for a 12-week vitamin D 
intervention trial in obese and normal-weight subjects, 
which has been described in detail elsewhere (6). In short, 
the study was conducted at the Children’s Hospital, Helsinki 
University Central Hospital, Finland. All participants 
were of Caucasian origin. Subjects with childhood-onset 
obesity (in the text referred to as obese) were identified 
from the Hospital’s patient registry and those fulfilling 
the following criteria were eligible to participate: 
(i) weight-for-height ratio exceeding 60% (corresponding 
to age and sex-specific BMI ≥99th percentile) before the 
age of 7  years, according to Finnish growth standards 
(13) and persistence of severe obesity for at least 3 years 
in childhood and (ii) follow-up during childhood at the 
Children’s Hospital, Helsinki University Hospital due to 
severe obesity. Among obese subjects, known endocrine 
and genetic disorders underlying obesity were excluded. 
We recruited normal-weight controls with a similar age 
range (in the text referred to as normal-weight) from the 
national population register and excluded subjects with 
childhood-onset obesity (weight-for-height ratio above 
40% before the age of 10 years). Other exclusion criteria 
included sunny holidays in the 2  months preceding 
the trial. Habitual supplement use was not an exclusion 
criterion in the present study but subjects were advised to 
maintain their current dietary habits during the study. All 
study participants and guardians of minors gave informed 
written consent before joining the study. The Research 
Ethics Committee of the Hospital District of Helsinki and 
Uusimaa approved the study (295/13/03/03/2012), and it 
is registered at ClinicalTrials.gov (NCT02549326).
Intervention was double-blinded, obese and normal-
weight subjects were randomised into two groups, receiving 
either placebo or cholecalciferol 50 µg (2000 IU) daily 
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(Minisun®, Verman, Kerava, Finland). The study protocol 
included three study visits: baseline (1st time point in 
the text), at 6  weeks (2nd time point) and at 12  weeks 
(3rd time point). During each visit, a fasting blood sample 
was collected between 8 and 10 h in two PAXgene Blood 
RNA Tubes (2.5 mL, PreAnalytiX GmbH, Hembrechtikon, 
Switzerland). Two hours after sampling, the PAXgene 
tubes were transferred to a −80°C freezer for storage and 
later analysis.
Methods
RNA samples
Total RNA from the PaxGene RNA tube was extracted 
using the PaxGene RNA kit (PreAnalytiX GmbH, 
Hembrechtikon, Switzerland) according to the 
manufacturer’s instructions. Genomic DNA was removed 
from the whole-blood samples using the DNA-free kit 
(Ambion), leaving the total RNA fraction. RNA integrity 
numbers (RINs) were assessed on an Agilent Bioanalyzer 
2100 at the Biomedicum Functional Genomics Unit 
(FuGU), Helsinki, Finland. RNA concentrations were 
measured using a Thermo Fisher Qubit 2.0 Fluorometer.
Library prep
An 80 ng sample of whole-blood RNA was treated 
using GlobinLock oligonucleotides (14) to mask globin 
transcripts before cDNA synthesis and significantly 
reduce the proportion of globin α and β reads in the 
sequencing data. This was followed by RNA sequencing 
using a modified version of the single-cell tagged reverse 
transcription (STRT) method (15) described in detail 
elsewhere (16).
Sequencing
The Illumina-compatible library pool was sequenced on 
four lanes each using the Illumina HiSeq2000 instrument 
and Illumina TruSeq v3 (Illumina) 60-bp single-read 
protocol. Sequencing was carried out at the BEA core facility 
at Karolinska Institutet, Huddinge, Sweden. Sequence data 
were converted to fastq files using Casava 1.8.2 (Illumina), 
and quality control performed using the STRTprep pipeline 
available at https://github.com/shka/STRTprep (16).
Gene ontology/pathway analyses
The DAVID database (v6.8 at https://david.ncifcrf.gov/
home.jsp, accessed 22 October 2017) was used to identify 
enriched gene ontology (GO) categories (GO BP_FAT, 
GO MF_FAT and GO_CC_FAT) and KEGG (17) pathways 
within the set of differentially expressed genes. The full 
list of significantly upregulated or downregulated genes 
was used in all pathway analyses.
qPCR validation
Five genes, with robust expression and significantly 
different expression levels in obese subjects in placebo 
and vitamin D group at the 6-week time point, were 
selected for technical validation by reverse transcriptase 
qPCR analysis. We included three obese subjects from 
the vitamin D group and three from the placebo group 
at the second time point and used the same RNA that 
was used for the initial whole-transcriptome analysis. 
cDNA was transcribed from 1 μg of total RNA using the 
QuantiTect Reverse Transcription Kit cDNA synthesis kit 
(Qiagen) according to the manufacturer’s protocol. qPCR 
assays were performed in quadruplicates with using the 
CXF96 Real-Time system (Bio-Rad Laboratories) and using 
the TaqMan ATP6V1F, COX5A, NDUFA2, ACTB and TBP 
gene expression assays Hs00855096_g1, Hs00362067_m1, 
Hs04187282_g1, Hs99999903_m1 and Hs00427620_m1, 
respectively (Applied Biosystems). ACTB and TBP were 
used as reference genes for data normalization. Threshold 
cycle (Ct) values were determined using CFX Manager 
Software (Bio-Rad Laboratories). Relative expression was 
calculated using the comparative Ct or 2ΔΔCt method 
(18, 19).
Serum biochemical markers
Laboratory methods concerning measurements of total 
25-OHD, free 25-OHD, insulin, adiponectin and high-
sensitive C-reactive protein (hs-CRP) are described in 
detail elsewhere (6, 20). In brief, serum total 25-OHD 
was measured with an automated IDS-iSYS analyser 
(IDS Ltd., Boldon, UK) with coefficient of variation (CV) 
<5% and compared against in-house liquid chromatography 
in tandem with mass spectrometry (20), and free 25-OHD 
was assessed using a two-step immunoassay (Future 
Diagnostics BV, Wijchen, Netherlands) with CV <8.5%. 
Plasma glucose was analysed by spectrophotometric a 
hexokinase and glucose-6-phosphate dehydrogenase assay 
(Gluko-quant glucose/hexokinase, Roche Diagnostics) 
with a Hitachi Modular automatic analyser (Indianapolis, 
USA). Serum insulin was measured using a time-resolved 
immunofluorometric assay (Perkin Elmer Life Sciences) with 
a detection limit of 0.5 mU/L and an interassay-CV <4%. 
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Serum adiponectin was determined using a Human Total 
Adiponectin/Acrp30 Quantikine ELISA Kit and serum 
leptin with Human Leptin R Quantikine ELISA Kit (R&D 
Systems) with intra- and inter-assay CV of <12%. hs-CRP 
was determined by an immunoturbidimetric assay on a 
Roche-automated clinical chemistry analysed at the central 
laboratory of the Helsinki University Central Hospital.
Statistical methods
Baseline characteristics between obese and normal-weight 
groups were compared separately with t-tests, and in case 
of categorical variables, using a Fisher’s exact test. Changes 
in total and free 25-OHD, insulin, hs-CRP, adiponectin 
and the proportion of white blood cells between three 
time points were compared using the repeated-measures 
ANOVA. We tested changes over time and responses 
as area under the curve between groups of interest. 
Differences were considered significant at P < 0.05. All 
statistical analyses were conducted using the IBM SPSS 
program for Windows, version 22 (IBM).
The STRTprep pipeline uses SAMstrt (21) to identify 
differentially expressed genes; the differences were 
considered significant at fluctuation P values <0.05 
and difference q values <0.05. The fluctuation is a test 
of alternative hypothesis that the biological CV in the 
samples is larger than the square of the technical CV; 
the technical CV is estimated by spike-in RNAs (16). The 
difference between the sample groups is a test of the 
alternative hypothesis that the distribution of expression 
levels in one group is stochastically greater than the 
other (21). The fluctuation P values were corrected by the 
Benjamini and Hochberg method, and difference q values 
were corrected using the Storey and Tibshirani method.
The significance of pathway and GO category 
enrichments was assessed using q values, which are 
P values adjusted using the Benjamini–Hochberg method 
for multiple hypothesis testing.
Results
Clinical characteristics of the intervention cohort
Baseline characteristics are shown in Table  1 for each 
of the four groups: obese + placebo (O_P), obese with 
vitamin D (O_VD), normal-weight + placebo (NW_P) 
and normal-weight + vitamin D (NW_VD). Serum 
biochemical markers and anthropometric measurement 
did not differ between obese groups, except for 
hs-CRP, which was higher in O_P compared with 
O_VD. Correspondingly, the characteristics did not 
differ between normal-weight groups. At baseline, 
the fraction of subjects with vitamin D deficiency 
(25-OHD ≤50 nmol/L) was 3/9, 5/7, 1/8 and 3/8 in the 
O_P, O_VD, NW_P and NW_VD groups, respectively. The 
response to vitamin D supplementation was observed in 
both the total and free 25-OHD concentrations (P < 0.001): 
The obese subjects had a lower response in total 25-OHD 
but a similar free 25-OHD when comparing the O_VD and 
NW_VD groups (Fig. 1). There were no changes in insulin 
(repeated-measures ANOVA: P = 0.475), hs-CRP (P = 0.062) 
or adiponectin (P = 0.263) levels during the 12 weeks and 
these did not differ between the four groups (ANOVA 
P = 0.278, P = 0.753 and P = 0.516, for insulin, hs-CRP and 
adiponectin, respectively).
RNA samples and sequencing
The RNA samples were of high quality (RIN >8, in all 
samples) and similar in all groups. Supplementary Table 1 
(see section on supplementary data given at the end of 
this article) shows the results of the sequencing analysis 
in both normal-weight and obese individuals, at three 
time points, including number of reads per sample and 
proportion of sequencing reads aligning to the 5´ends of 
coding genes. Five samples were removed from further 
analysis (two due to low RNA quality, three due to low 
yield of RNA ERCC spike-in). Each sample had on average 
>6 million sequence raw-reads, and on average, >5 
millions of those mapped to the human genome (hg19). 
No significant differences between the quality of the 
libraries, between different treatments or time points were 
seen (data not shown).
Differential expression analysis
A comparison of the gene expression in the vitamin D and 
placebo groups was performed separately in the obese and 
normal-weight subjects at the three time points. Principal 
component analysis (PCA) plots for each comparison 
are shown in Supplementary Fig.  1 and the full dataset 
of normalised expression values for each subject and 
time point, and each detected gene, can be found in 
Supplementary Dataset 1. In normal-weight subjects, the 
differences in gene expression between the vitamin D and 
placebo groups were not significant at any time point.
Significant fold-changes were observed only at the 
second time point in the obese individuals (Table 2 and 
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Supplementary Table 2), between the placebo (O_P) and 
vitamin D (O_VD) groups, and thus, we proceeded further 
only with these samples. Figure  2 shows a hierarchical 
clustering of the samples from obese individuals at the 
second time point and a heatmap of the differentially 
expressed genes (1724 upregulated genes and 186 
downregulated, in vitamin D supplemented compared 
with placebo receiving individuals). Individuals receiving 
vitamin D and placebo cluster separately, except for one 
individual in placebo group. The study was underpowered 
to look at changes in gene expression within subjects 
(data not shown). Still, we provide pairwise analyses of 
the top three upregulated and downregulated genes in 
Supplementary Figs  2 and 3 to support our group-wise 
comparisons.
qPCR validation
The qPCR results of ATP6V1F, COX5A and NDUFA2 
gene expression were in line with the results of the STRT 
RNA-seq data (Supplementary Fig.  4). The expression 
of ATP6V1F (Independent samples t-test: P = 0.003) and 
COX5A (P = 0.002) differed between the vitamin D (O_VD) 
and placebo (O_P) groups: a significant upregulation was 
observed with vitamin D compared with the placebo 
group at the 6-week time point in the obese ones. There 
were no significant differences between groups in the 
expression of NDUFA2 (P = 0.29) most likely due to low 
sample size.
Pathways
In order to understand the potential mechanism 
underlying vitamin D response at the transcriptome level, 
we performed GO category and KEGG pathway analysis 
of the differentially expressed genes. Supplementary 
Dataset 2 shows the significant or top 25 GO categories 
(BP, MF and CC) that were enriched in the list of genes 
upregulated upon vitamin D supplementation in the 
obese individuals. The enriched GO-BP categories 
(representing biological processes) include the immune 
response and nucleoside metabolic processes. The 
cellular component categories (GO-CC) highlight the 
mitochondrial membrane. Lastly, the enriched GO-MF 
(molecular function) categories involve RNA binding, 
cadherin binding and transmembrane ion transport. 
Supplementary Dataset 2 shows the GO categories that 
were enriched in downregulated genes.
Figure  3 shows the top 10 upregulated KEGG 
categories in the vitamin D-supplemented obese group 
(O_VD) at the 6-week time point. Supplementary Dataset 
3 shows the full list (n = 14) of significant pathways. 
The most significantly enriched category was oxidative 
phosphorylation (hsa:00190) with an adjusted P value 
of 3.08 × 10−14. Figure  4 summarises all significantly 
differentially expressed genes in this pathway, highlighted 
with a red asterisk. The other top enriched pathways include 
Alzheimer’s disease, Huntington’s disease and Parkinson’s 
disease. While the names of these pathways imply a 
connection to a specific disease, looking further into the 
Table 1 Cohort characteristics with mean (s.d.), unless otherwise noted.
O_P O_VD NW_P NW_VD P value_O P value_NW
N 9 7 8 8    
Maleb 7/9 4/7 4/8 5/8 0.596a 0.608a
Age (years) 18.9 (2.4) 19.8 (3.2) 21.9 (2.2) 21.1 (2.4) 0.533 0.502
BMI (kg/m2) 38.8 (13.3) 34.4 (6.6) 22.0 (2.8) 25.2 (5.3) 0.403 0.168
Waist (cm) 117.8 (29.6) 104.7 (19.3) 74.0 (7.0) 83.2 (14.0) 0.306 0.127
S-25-OHD (nmol/L) 55.8 (13.6) 44.9 (13.0) 66.0 (23.7) 51.8 (17.4) 0.128 0.197
Free 25-OHD (pg/mL) 3.4 (1.3) 2.6 (1.1) 5.0 (1.9) 4.1 (1.7) 0.219 0.323
Free/total 25-OHD × 102 6.20 (2.20) 5.80 (1.51) 7.78 (2.33) 7.84 (1.27) 0.682 0.945
Insulin (mU/L) 13.8 (7.8) 15.8 (9.2) 5.4 (2.7) 9.7 (5.9) 0.647 0.091
hs-CRP (mg/L) 7.55 (7.2) 0.87 (0.5) 0.79 (0.6) 0.68 (0.8) 0.024 0.773
Adiponectin (ng/mL) 3760 (2327) 5180 (2689) 10221 (7316) 10615 (6216) 0.288 0.909
Gc genotype 1/1b 5/9 5/7 8/8 6/8 0.633a 0.467a
White blood cell count, cells × 109/L 7.8 (2.4) 6.8 (1.1) 4.4 (1.2) 5.4 (1.9) 0.341 0.231
Neutrophils 4.2 (1.3) 3.2 (1.1) 2.1 (0.9) 2.6 (1.1) 0.125 0.289
Lymphocytes 2.7 (1.1) 2.7 (0.8) 1.7 (0.4) 2.1 (0.7) 0.971 0.213
Monocytes 0.55 (0.17) 0.62 (0.14) 0.39 (0.08) 0.49 (0.17) 0.398 0.163
Eosinophils 0.25 (0.17) 0.25 (0.21) 0.25 (0.21) 0.19 (0.13) 0.992 0.524
Basophils 0.04 (0.03) 0.02 (0.01) 0.03 (0.02) 0.04 (0.03) 0.200 0.949
aFisher’s exact test; bfraction.
NW_P, normal-weight + placebo; NW_VD, normal-weight + vitamin D; O_P, obese + placebo; O_VD, obese + vitamin D; P value_O, P value for the 
comparison of obese groups; P value_NW, P value for the comparison of normal-weight groups.
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genes involved instead shows that they show considerable 
overlap with the oxidative phosphorylation pathway 
(Supplementary Fig.  5), with 51.8% of the differentially 
expressed genes in these pathways being shared by all four 
pathways. Thus, it is clear that the four pathways largely 
overlap, despite their names, and the common factor 
is genes involved in mitochondrial function. A second 
group of enriched KEGG pathways is related to immune 
responses including phagosome (hsa04145) and antigen 
processing and presentation (hsa04612) pathways. Only 
one KEGG pathway, hsa03010:ribosome, was significantly 
enriched in the set of downregulated genes (adjusted 
P value 6.54 × 10−7).
Discussion
In the present study, we applied the recently published 
GlobinLock technology (14) to minimise globin RNA 
contamination when performing transcriptome analysis 
on RNA from circulating white blood cells. Our results 
do not allow the study of the tissue-specific actions of 
vitamin D, for example, in adipose tissue, but they 
give an overview of the global transcriptomic effects 
of vitamin D. Our study shows for the first time that 
vitamin D supplementation has an impact on gene 
expression in circulating white blood cells of obese 
individuals, an effect which was not observed in normal-
weight subjects. A part of the affected genes are enriched 
in pathways related to immune responses, which is in 
line with previous findings (10, 11, 22). The strongest 
transcriptomic effects, however, are those connected to 
mitochondrial function.
Oxidative pathway
An activation of the oxidative phosphorylation pathway 
by vitamin D supplementation was observed in obese 
subject in our study. To our knowledge, there is no 
comparable study available. Oxidative phosphorylation 
is a part of the energy-producing pathway within the 
mitochondrial inner membrane and exerts its actions 
on cellular energy production. Several studies have 
reported reduced mitochondrial number, size and 
activity in skeletal muscle and adipose tissue in patients 
with obesity and type 2 diabetes (23, 24, 25). In fact, 
mitochondrial dysfunction is suggested to precede the 
development of insulin resistance (26, 27). In a recent 
metabolomics study, the metabolic signature differed 
between obese children with and without insulin 
resistance, and the enriched and the most altered 
pathways included the urea cycle, alanine metabolism 
and the glucose–alanine cycle, also connected to 
mitochondrial function (28).
Using a systematic approach, we detected significant 
upregulation of altogether 53 of the approx. 130 genes in the 
KEGG oxidative phosphorylation pathway in obese subjects 
receiving vitamin D supplementation. A link between 
vitamin D and mitochondria function has been reported 
previously in experimental models (29, 30, 31, 32, 33, 34), 
A
B
C
Figure 1
Change in serum total (A) and free (B) 25-OHD concentrations and their 
adjusted ratio (C) in the four groups: obese + placebo (O_P), 
obese + vitamin D (O_VD), normal-weight + placebo (NW_P), and 
normal-weight + vitamin D (NW_VD) with mean and SEM during the 
12-week study.
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this was recently summarised by Ricca et  al. (35): 
1,25(OH)2D limits excessive mitochondrial respiratory 
activity and ROS production and turns cell metabolism 
toward biosynthesis and proliferation. A number of these 
effects are highly cell type specific. Our finding that 
the uncoupling protein 2, UCP2, is upregulated upon 
vitamin D supplementation is not in line with previous 
observations (30, 31, 32). This may be due to differences 
in timing, discordance in phenotypes or for example in 
the severity of the vitamin D deficiency.
Table 2 List of top 50 up- and downregulated genes in the obese group with vitamin D (see Supplementary Table 2 for full list).
Upregulated Downregulated
Gene DiffexpScore q value Gene DiffexpScore q value
TAPBP 24.00 0.01 HBQ1 −16.15 0.01
XAB2 23.95 0.01 TUBGCP3 −14.10 0.01
CHERP 23.90 0.01 KANK2 −14.00 0.01
ETHE1 23.90 0.01 FUNDC2 −13.00 0.01
ITGB1BP1 23.75 0.01 AK1 −11.75 0.01
DECR1 23.50 0.01 SLC25A37 −11.60 0.01
EFTUD2 23.35 0.01 FAM210B −11.30 0.01
RASGRP4 23.25 0.01 MTRNR2L9 −11.30 0.01
CFLAR 23.15 0.01 EPB42 −11.20 0.01
ABI3 23.10 0.01 UBB −10.85 0.01
FAM127A 23.05 0.01 HEMGN −10.70 0.01
MAZ 22.95 0.01 GCAT −10.05 0.01
SIRT7 22.85 0.01 BIRC2 −10.00 0.01
PSAP 22.75 0.01 TMEM176B −9.80 0.01
IFI27L2 22.70 0.01 HMBS −9.20 0.01
TMEM161A 22.70 0.01 HBB −8.90 0.01
CXCR3 22.65 0.01 MICALL2 −8.85 0.01
VIM 22.65 0.01 AHSP −8.40 0.01
MYO1G 22.60 0.01 OPTN −8.35 0.01
SLC25A3 22.60 0.01 RNF10 −8.30 0.01
CALM1 22.55 0.01 HBG2 −8.25 0.01
SERPING1 22.55 0.01 MYL4 −8.20 0.01
C12orf75 22.50 0.01 GMPR −8.15 0.01
CRTC2 22.45 0.01 KLC3 −8.10 0.01
ZFP36L2 22.45 0.01 TMEM176A −7.95 0.01
GSTP1 22.30 0.01 HBD −7.90 0.01
SEPT9 22.30 0.01 GSTM1 −7.70 0.01
PEF1 22.25 0.01 ISCA1 −7.60 0.01
RHBDF2 22.25 0.01 CA1 −7.15 0.01
PRAM1 22.20 0.01 LYPD2 −6.80 0.01
ANXA2 22.15 0.01 SLC22A16 −6.80 0.01
CHI3L1 22.15 0.01 GSTM3 −6.75 0.01
DHCR7 22.15 0.01 HAGH −6.75 0.01
MRPL43 22.15 0.01 MTRNR2L2 −6.75 0.01
TP53I13 22.15 0.01 PPP1R3B −6.45 0.01
HMGA1 22.10 0.01 PNP −6.40 0.01
SQSTM1 22.05 0.01 YBX1 −6.35 0.01
CD7 22.00 0.01 C7orf73 −6.25 0.01
CD74 22.00 0.01 PRDX6 −6.15 0.01
MGST3 22.00 0.01 DHX16 −6.00 0.01
PLD3 21.95 0.01 ADIPOR1 −5.95 0.01
EMD 21.90 0.01 SLC2A1 −5.95 0.01
TRAPPC2L 21.90 0.01 RUNX2 −5.90 0.01
CHTF8 21.85 0.01 STRADB −5.80 0.01
ARSA 21.80 0.01 TESC −5.80 0.01
ATP5G3 21.80 0.01 FAM104A −5.75 0.01
SSH3 21.80 0.01 C6orf48 −5.70 0.01
ARHGAP1 21.75 0.01 EIF1AY −5.70 0.01
ATF5 21.75 0.01 RNF175 −5.60 0.01
PDHB 21.70 0.01 ACKR1 −5.55 0.01
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Obesity-specific effects
Interestingly, the transcriptomic effect of vitamin D was 
seen only in obese individuals. A plausible explanation for 
this is that the obese are more likely to have dysfunction 
of mitochondria and in the oxidative phosphorylation 
than normal-weight individuals. If we use fasting insulin 
concentration as a proxy for metabolic health, we notice 
that obese individuals in our cohort had higher median 
values and more variation in insulin concentrations 
compared with controls. Abnormally high fasting insulin 
concentrations (≥12 mU/L) (36) were also mostly observed 
Figure 2
Hierarchical clustering of samples based on the 
expression of differentially expressed genes 
(vitamin D treatment compared with placebo). 
Red for higher and blue for lower expression.
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Figure 3
The ten most significantly enriched KEGG 
pathways in genes upregulated by vitamin D 
treatment compared to placebo. The number of 
upregulated genes within each pathway is shown.
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in the obese subjects. Furthermore, it has been shown that 
mitochondrial dysfunction decreases adiponectin secretion 
in adipocytes, resulting in lower glucose uptake in muscle 
(37) and adipocytes (38). In line with this, we observed lower 
adiponectin concentrations in the obese groups compared 
with the normal-weight groups. At baseline, the frequency 
of vitamin D deficiency was more common in obese than in 
normal-weight subjects, which is an alternative explanation 
to our finding. Hence, the vitamin D supplementation 
might have a stronger corrective effect in those with 
vitamin D deficiency. Limited sample size precluded 
addressing the confounders in more detail. On the 
other hand, the ratio of free-to-total 25-OHD, reflecting 
availability of vitamin D at the tissue level, differed at the 
second time point between the obese groups. This might also 
be the explanation for the observed transcriptomic effects.
Implication for further studies or for 
other phenotypes
Our findings on transient effects are novel, but these need 
to be replicated. However, they potentially have several 
implications for future research not only in obesity but 
also in public health. Mounting evidence links vitamin D 
deficiency to the development of type 2 diabetes 
(39, 40), but the exact mechanism has remained 
inconclusive at least in humans. It is widely accepted that 
impaired mitochondrial function and insulin resistance 
are related. Thus, vitamin D supplementation may have 
far-reaching consequences on insulin resistance, which 
is supported by some animal (41) and human studies 
(42), although not consistently (43). Correspondingly, 
vitamin D deficiency has been linked to Parkinson’s 
disease (44, 45) and Alzheimer’s disease (44) but only a 
single study has linked it to Huntington’s disease (46). Our 
study supports these associations, presumably through 
the shared mitochondrial mechanism.
Timing
The most pronounced effect of vitamin D on the 
transcriptome is seen at 6 weeks after the initiation of the 
vitamin D supplementation, which is a novel finding. The 
effect was already less clear again at the 12-week time point. 
Figure 4
Schematic of the major components of the KEGG oxidative phosphorylation pathway, from the DAVID bioinformatics portal (https://david.ncifcrf.gov/). 
Genes significantly upregulated at the second time point in obese subjects receiving vitamin D are marked with a red star.
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This might be related to the vitamin D turnover rate in 
the body (or saturation level), which depends on the 
dose of vitamin D, baseline 25-OHD concentration and 
polymorphism of vitamin D-related genes (47, 48, 49). 
Similarly, we and others have demonstrated with multiple 
doses of vitamin D that the effect on circulating 25-OHD 
plateaus after 6 weeks (47, 50). The catabolizing enzyme 
CYP24A1 is known to initiate the degradation pathway 
of 25-OHD (10), but the expression of CYP24A1 was not 
detected in the present study, likely due to the rather 
tissue-specific expression of this protein. In a Norwegian 
study, long-term vitamin D supplementation induced 
only minor changes in whole-blood gene expression in 
47 overweight senior citizens with prediabetes (51). The 
global transcriptome was analysed at a single 50-month 
time point. In a subgroup analysis of the low versus 
high 25-OHD group, differences in the expression of 198 
mRNAs was observed. The affected genes were enriched 
within pathways involving oxidative stress response, 
apoptosis signalling and gonadotropin-releasing hormone 
receptor. These authors suggested that short-term effects 
of vitamin D supplementation, which is what we look at 
in our current study, are likely to have a more prominent 
effect on global transcriptome than a long-term study.
On the contrary, a more recent, randomised, placebo-
controlled trial, supplementing older English men 
with high doses of vitamin D for 12  months detected 
no significant effect on gene expression or circulating 
cytokine concentrations (52). It is likely that they missed 
the early transcriptomic changes, since the sampling was 
performed only at baseline and 12 months.
Strengths and limitations
Our study has several limitations, including the 
descriptive nature of the study and due to removal of 
samples failing quality control, the groups were not 
equal-sized, which resulted in a loss of statistical power. 
The total amount of RNA in the sequencing was the same 
in each sample, and since the proportion of cell types did 
not differ between the groups and did not change with 
time within the groups, our findings are not likely to 
be confounded by cell type distributions. Reassuringly, 
we did not observe significant transcriptome differences 
between the obese groups at baseline. A more general 
limitation is that the transcriptome of blood cells serves 
merely as a proxy of an endocrine phenotype. The mRNA 
transcriptome furthermore represents only a snapshot of 
the ongoing processes. Despite the intervention trial, 
the study could not prove causality, and the possibility 
of indirect effects mediated by calcium fluxes remains 
unsolved (31).
The current study can be regarded as a pilot study 
or descriptive study on the transcriptomic effects of 
vitamin D supplementation due to lack of functional 
outcomes. Future work should ideally be expanded to 
larger cohorts and to include analyses of multiple tissues 
and to verify these findings at the protein level and link 
them with endocrine and metabolic parameters.
Conclusions
Here, we demonstrate that vitamin D supplementation 
affects gene expression in young obese subjects 
supplemented with a daily dose of vitamin D (50 μg) and 
the affected genes are enriched within pathways related 
to mitochondrial function. The present study increases 
our understanding of the effects of vitamin D at the 
transcriptome level but is not conclusive and should 
be regarded as pilot data for future studies. Our results 
may be valuable for considering the effects of vitamin D 
supplementation in obese individuals and when evaluating 
the adequacy and safety of the supplementation dose.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-18-0537.
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